Instituto Médico de la Fundación Estudios Clínicos - Rosario
Instituto Médico de la Fundación Estudios Clínicos - Rosario
Italia 428, Rosario - Santa Fe
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Elizabeth Cuesta
Gustavo Braidot
Valentina Ermini
Maria Fernanda Ghiara
Norma Jacobi
Sofia Perotti
Florencia Tubino
Juan Andrés Oddino
Martin Camilo Azum
Maria Soledad Marigó
Mariana Perrin
Victoria Pizurno
Javier Travella
Aldana Lipari
Luciana Zanchi
Gabriel Garbaos
Guillermo Ortiz
Leticia Maria Bruno
Virginia Van Kemenade
Juan Fernando Piana
Betiana Romitelli
Ana Sol Capelleti
German Antonio Arce
Daiana Bellier
Nadia Brandan
Melina Ballester
Gabriel Gattolin
Mariano Buteler
Daniel Sotelo
Agustina Genesio
Cecilia Lonegro
Ignacio Magri
Open studies
Breast Cancer
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) - evERA - Genentech, Inc.See more
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) - CAPItello-292 - AstraZenecaSee more
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer - TROPION-Breast05 - AstraZenecaSee more
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer - OPERA-01 - Olema Pharmaceuticals, Inc.See more
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) - MK 2870-010 - Merck Sharp & Dohme LLCSee more
Lung cancer
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer - STAR-121 - Arcus Biosciences, Inc.See more
Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC - MB12-C-01-22 - Laboratorio Elea Phoenix S.A.See more
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) - INTerpath-002 - Merck Sharp & Dohme LLCSee more
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) - Dizal PharmaceuticalsSee more
Hypercholesterolemia
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn - Merck Sharp & Dohme LLCSee more
Nephropathy
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) - Alexion PharmaceuticalsSee more
A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression - IMAGINATION - Hoffmann-La RocheSee more
Bile Duct Cancer
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer - Jazz PharmaceuticalsSee more
Cardiovascular disease
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Chronic bronchitis
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) - PILASTER - Chiesi Farmaceutici S.p.A.See more
Chronic obstructive pulmonary disease
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) - PILASTER - Chiesi Farmaceutici S.p.A.See more
Colorectal cancer
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer - MOUNTAINEER-03 - Seagen Inc.See more
Crohn's disease
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease - CULTIVATE - Arena PharmaceuticalsSee more
Depression
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy - VENTURA-1 - Janssen Research & Development, LLCSee more
Esophageal cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) - LEAP-014 - Merck Sharp & Dohme Corp.See more
Leukemia
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
Lymphoma
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
Multiple myeloma
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) - SUCCESSOR-2 - Bristol-Myers SquibbSee more
Rare diseases
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
Schizophrenia
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2) - CONNEX-1 CONNEX-2 CONNEX-3 - Boehringer IngelheimSee more
Ulcerative colitis
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) - LUCENT 3 - Eli Lilly and CompanySee more
